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Poorly diﬀerentiated thyroid
carcinoma
An underdiagnosed entity
Background
Theodor Langhans described a malig-
nant thyroidcarcinoma in1907, whichhe
termed “rampantly goiter” or “wuchern-
de Struma” in German [30]. While this
entity was well received in the German
literature and textbooks [41], the term
“poorlydiﬀerentiatedthyroidcarcinoma”
(PDTC) was ﬁrst introduced by Granner
and Buckwalter in the early 1960s to the
English-speaking audience. At that time,
clear diagnostic criteria were not pro-
vided [21].
Withpathologydevelopingamorecri-
teria-based approach, two groups inde-
pendently published diﬀerent diagnostic
criteria in 1983/1984 to allow for the di-
agnosis of PDTC [12, 44]. Sakamoto
et al. postulated the frequency of PDTC
at about 14% in a series of 258 thyroid
carcinomas [44]. The other group re-
ferred to Langhans’ so-called wuchernde
Struma, which he introduced 1907 and
which may in fact be the ﬁrst description
of a PDTC in the literature [12].
The two schools of thought remained:
While one school placed more empha-
sis on the growth pattern of the lesion
(trabecular, insular, or solid), the other
group used typical features of high-grade
lesions like atypia, tumor necrosis, or
a high mitotic index [1, 12, 38, 44, 49,
54]. It took another 20 years for this
entity to be accepted and introduced in
the World Health Organization (WHO)
series of malignant human neoplasms in
The German version of this article can be
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2004 [13] and since then it has been a rec-
ognized entity [33].
Both of the aforementioned groups
recognized the concept of a thyroid tu-
mor that is placed biologically between
well-diﬀerentiated thyroid carcinomas
like papillary thyroid carcinomas (PTC)
or follicular thyroid carcinomas (FTC)
with an excellent prognosis and the
extremely aggressive anaplastic thyroid
carcinomas (ATC; [36]). However, both
groups oﬀered signiﬁcant diﬀerent di-
agnostic approaches to allow for such
a diagnosis. Obviously, diﬀerent diag-
nostic algorithms and criteria led to an
increased uncertainty of these lesions
and, consequently, studies were not com-
parable. While some integrated tumors
that we would classify as PDTC today,
others also included the tall cell variant
of PTC, which today would fall into the
category of well-diﬀerentiated thyroid
carcinomas (however, with an adverse
outcome; [27, 45]).
Diagnostic algorithm
In order to unify the concepts of PDTC,
a group of internationally recognized
thyroid experts met in 2006 in Turin and
elaborated the so-called Turin criteria,
which are a diagnostic algorithm, based
on both schools of thought: high-grade
features and growth pattern (. Fig. 1
and 2; [53]). This algorithm is now
accepted and integrated in the WHO
classiﬁcation [33].
After identiﬁcation of malignancy
(angioinvasion and/or gross invasion),
a so-called STI pattern (solid, trabecular,
or insular growth pattern) is the ﬁrst hint
of the diagnosis of PDTC. It is worth
pointing out that PDTC may on rare
occasions be completely encapsulated
and even without angioinvasion. These
cases are prone to be misdiagnosed as
adenomas if the pathologist in charge is
not familiar with the concept of PDTC.
One has to look for PTC nuclei
throughout the lesion in order to ex-
clude the solid variant of PTC. If this
feature is absent, one of the three fol-
lowing features is enough to allow for
the diagnosis of a PDTC to be made:
1. convoluted nuclei that are a bit
smaller than those of a PTCwhile also
having a wrinkled irregular contour
that overall gives them a raisinoid-
like appearance. Nevertheless, their
chromatin is much darker and evenly
distributed and their overall appear-
ance is more uniform than in PTC
nuclei. Nuclear pseudoinclusions are
absent while one may observe some
nuclear grooves. If pseudoinclusions
are present, they may be seen as
a sign of tumor progression from
a PTC to a PDTC, and if enough
tumor material is embedded, classic
PTC remnants may be seen in such
cases [36].
2. Tumor necrosis also allows for the
diagnosis of a PDTC in this ﬂowchart,
usually seen as a small necrotic focus
within a solid tumor cell nest. Single
cell necrosis does not count, and it is
essential to exclude tumor necrosis
followed by ﬁne-needle aspiration
(FNA), which happens frequently
especially in oncocytic nodules.
3. The last criterion is an increased mi-
totic activity of at least three mitoses
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Fig. 19 Diagnostic
algorithm for the
diagnosisofapoorly
diﬀerentiated thy-
roid carcinoma
(PDTC). FTC follicular
thyroid carcinomas,
PTCpapillary thy-
roid carcinomas,
STI solid, trabecular,
or insular growth,
PDpoorly diﬀer-
entiated,HPFhigh
power ﬁeld
per ten high-power ﬁelds. This cut-
oﬀ exhibited a good correlation with
survival data in the cases used in
the Turin consensus meeting; how-
ever, the amount of mitosis per mm2
needed was unfortunately not deﬁned
[54].
Applying the correct Turin criteria,
PDTCs are—as already indicated in the
title—rare lesions. Over a time spanof 26
years and in a population of 1.37 million
inhabitants, we were able to identify 34
PDTC carcinomas [15]. In that study,
only one tumor was diagnosed as PDTC
in the original pathology report, indi-
cating that the concept of PDTC is not
yet well known and must be used more
widely in everyday practice [14].
Currently, the incidence of PDTC in
Europe is estimated at 4–7%of all thyroid
carcinomas, which corresponds to 240
new cases in Germany each year.
The incidence of indolent thyroid car-
cinomas has been rising for many years
and as a consequence many patients get
overtreated [34]. On the other hand,
PDTCs, which require a correct diagno-
sis inorder to receive adequate treatment,
are often missed in daily routine.
Fine-needle aspiration
The cytological diagnosis of PDTC on
FNA samples is challenging. This is due
to the rareness of the diagnosis, the non-
speciﬁc cytological features, the overlap
with cytological characteristic of follic-
ular neoplasms, and the frequently en-
countered sampling error of the PD com-
ponent in an otherwise well-diﬀerenti-
ated tumor. Thus, according to published
series, only 27% of cases were diagnosed
correctly as PDTC on FNA [3, 5, 28,
40], whereasmost of the remaining cases
were put into the category “(suggestive
of) follicular neoplasm”[6]. According to
a recent review and meta-analysis of the
literature by Saglietti et al., the presence
of insular or solid architecture, hypercel-
lularity, high nuclear/cytoplasmic ratio,
and mitotic activity can suggest the di-
agnosis of PDTC [43].
How much “poorly
diﬀerentiated” is needed?
It has long been known that there are
PDTCs with a minor and even a major
component of a well-diﬀerentiated thy-
roid carcinoma like PTC or FTC. Today,
it is believed that most of them arise in
a well-diﬀerentiated thyroid carcinoma,
although a subset of these lesions ap-
parently also arise de novo (. Fig. 3).
About 80% of PDTC have a PD com-
ponent of >50%, and only 20% of PDTC
have a minor PD component [14]. How-
ever, it was unclear in the Turin proposal
what percentage of poorly diﬀerentiated
was needed in a tumor to allow for such
a diagnosis and—more importantly—to
aﬀect patient prognosis; moreover, the
2004 WHO classiﬁcation did not oﬀer
a cut-oﬀ value [13]. We showed that even
a small PD component of 10% aﬀects pa-
tient prognosis equally negative as a tu-
mor that consists of 100% PD regarding
relapse-free survival or overall survival
[14, 33]. Our ﬁndings were recently con-
ﬁrmedbyothers [4] andarenowreﬂected
in the current WHO classiﬁcation [33].
Therefore, a thorough histological work-
up is highly recommended to ensure an
adequate diagnosis is made.
Oncocytic subtype—does it
matter?
Basedontheirneoplastic tumoroforigin,
PDTCs can be subdivided into papillary
type, follicular type, and not otherwise
speciﬁed (NOS). However, this subdivi-
sion does not have any clinical or prog-
nostic consequences [36].
Owing to a lack of data, oncocytic
carcinomas were excluded in the Turin
proposal and therefore it was initially un-
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known whether these criteria were also
applicable to oncocytic lesions. We re-
ported that the Turin criteria can also be
applied in this scenario [15]. However, it
should be emphasized that the presence
of necrosis in these tumors should not
be overestimated since oncocytic lesions
in general are prone to spontaneous or
FNA-initiated infarctionand focalnecro-
sis. Thus, one should carefully look for
signs of previous FNA in a given case.
Andwhile therelapse-freesurvival issim-
ilar betweenPDTCandoncocytic PDTC,
it is nevertheless very important to dis-
tinguish between PDTC and oncocytic
PDTC, since oncocytic PDTC may have
an even worse overall survival than con-
ventional PDTC [15].
Diﬀerential diagnoses
Poorly diﬀerentiated thyroid carcinoma
must bedistinguished frommalignant le-
sions that are not derived from follicular
epithelial cells such as medullary thy-
roid carcinomas or rarely metastases to
the thyroid, most often derived from the
kidney or lung [36]. Also, well-diﬀeren-
tiated thyroid carcinomas like PTC and
especially the solid variant of PTC needs
to be excluded on the basis of nuclear fea-
tures. The same is true for FTCs that do
not show an STI pattern. Of note, many
lesions that have been classiﬁed as widely
invasive FTC in the past, today fall into
the category of PDTC. And while there
is a progression from well-diﬀerentiated
thyroid carcinomas to PDTC, there may
also be a further progression to an ATC
that of course is prognostically relevant
and even the smallest ATC component
should be reported as well [50, 51].
TNM classiﬁcation
The current 8th edition of the TNM clas-
siﬁcation was introduced in 2017. Now,
all thyroid carcinomas includingATCare
similarly categorized intodiﬀerent tumor
stages [9]. One study explored the va-
lidity of the new classiﬁcation and while
it seems that a good prognostic separa-
tion for FTC can be achieved, neither the
7th nor the 8th edition is able to predict
accurately patient prognosis for PDTC
[26].
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Abstract
Poorly diﬀerentiated thyroid carcinomas
(PDTCs) are a rare subtype of thyroid carcino-
mas that are biologically situated between
well-diﬀerentiated papillary/follicular thyroid
carcinomas and anaplastic thyroid carcinomas
(ATCs).
The diagnosis of conventional as well as
oncocytic poorly diﬀerentiated thyroid
carcinoma is diﬃcult and often missed in
daily routine. The current WHO criteria to
allow the diagnosis of PDTCs are based on the
results of a consensus meeting held in Turin
in 2006. Even a minor poorly diﬀerentiated
component of only 10%of a given carcinoma
signiﬁcantly aﬀects patient prognosis and
the oncocytic subtype may even have a
worse outcome. Immunohistochemistry is
not much help and is mostly used to exclude
a medullary thyroid carcinoma with calcitonin
and to establish a follicular cell of origin via
thyroglobulin staining.
Due to the concept of stepwise dediﬀeren-
tiation, there is a vast overlap of diﬀerent
molecular alterations like BRAF, RAS, CTNNB1,
TP53 and others between diﬀerent thyroid
carcinoma subtypes. A distinctive molecular
tumor proﬁle is therefore currently not
available.
PDTCs have a unique miRNA signature,
which separates them from other thyroid
carcinomas. The average relapse free survival
is less than one year and about 50% of
patients die of the disease. Modern tyrosine
kinase inhibitors oﬀer in conjunction with
powerful molecular diagnostic new chances
in these diﬃcult to treat carcinomas.
Keywords
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Gering diﬀerenzierte Schilddrüsenkarzinome. Eine
unterdiagnostizierte Entität
Zusammenfassung
Gering diﬀerenzierte Schilddrüsenkarzinome
(PDTC) stellen einen seltenen Subtyp
des Schilddrüsenkarzinoms dar, welcher
biologisch zwischen den gut diﬀerenzierten
Schilddrüsenkarzinomen (papilläre und
follikuläre Schilddrüsenkarzinome) auf
der einen Seite und den anaplastischen
Schilddrüsenkarzinomen auf der anderen
Seite angesiedelt ist.
Die Diagnose des konventionellen wie des
onkozytären PDTC ist schwierig und wird in
der täglichen Routine oft verpasst. Derzeit
werden diese Tumoren nach Kriterien der
aktuelle WHO-Klassiﬁkation diagnostiziert,
welche in einer Konsensustagung 2006 in
Turin erarbeitet wurden. Selbst ein kleiner
Anteil eines PDTC von nur 10% innerhalb
eines Schilddrüsenkarzinoms beeinﬂusst die
Prognose nachhaltig und die onkozytäre
Variante hat einen nochmals ungünstigeren
Verlauf. ImmunhistochemischeAnalysen sind
meist nicht hilfreich und werden genutzt,
um ein medulläres Schilddrüsenkarzinom
mittels Calcitonin auszuschließen oder die
Follikelepithelzelle als Ursprungszelle mittels
Thyreoglobulin nachzuweisen.
Auf molekularer Ebene gibt es eine große
Überlappung unterschiedlicherMutationen in
den verschiedenen Schilddrüsenkarzinomen
wie BRAF, RAS, CTNNB1 oder TP53, welche
sich durch das Konzept der schrittweisen
Dediﬀerenzierung gut erklären lassen.
Entsprechend existiert nach wie vor
kein eigenständiges, für die Diagnostik
einsetzbares molekulares Proﬁl. PDTC haben
ein distinktes miRNA-Proﬁl im Vergleich
zu anderen Schilddrüsenkarzinomen. Das
durchschnittliche rezidivfreie Überleben liegt
unter einem Jahr und etwa 50% der Patienten
versterben an ihrem Tumor. Thyrosinkinas-
einhibitoren eröﬀnen gemeinsammit einer
leistungsstarken molekularen Diagnostik
neue Therapiechancen in diesen schwer zu
therapierenden Karzinomen.
Schlüsselwörter
Gering diﬀerenziertes Schilddrüsenkarzinom ·
MicroRNA · Prognose · Schilddrüsentumor ·
Thyrosinkinaseinhibitor
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Fig. 29 aObviouslyma-
lignant neoplasm, vascular
invasion and invasion into
adjacent tissue;b trabecu-
lar growthpattern; c insular
and solid growth pattern;
d tumor necrosis; emitosis
andpsammomabodies, no
papillary thyroid carcino-
mas (PTC) nuclei; f raisinoid
nuclei, trabecular growth
pattern;g upper part onco-
cytic poorly diﬀerentiated
thyroid carcinoma (PDTC),
lower part FTC;h PTC rem-
nants in a PDTC. Only archi-
tecture of PTC, no longer
any PTC nuclei
Immunohistochemistry
Immunohistochemical studies in thyroid
carcinomas in general and in PDTC in
particular have been performed [31] and
results are summarized in . Table 1. It
can be of help to establish a follicular cell
of origin and exclude amedullary thyroid
carcinoma, which would stain positive
for calcitonin [20] and neuroendocrine
markers [31]. Poorly diﬀerentiated thy-
roid carcinomas are typically positive for
thyroglobulin, although the expression
is often patchy and focal [2, 37]. Strong
and diﬀuse positivity of thyroglobulin is
typically found in the adjacent well-dif-
ferentiated carcinoma component.
Most of the diagnostic work-up,
however, is based on classic hema-
toxylin–eosin staining. Markers of ma-
lignancy in thyroid carcinomas like
Galectin-3 or HBME-1 have been ex-
plored, but there is no practical applica-
tion because signs of malignancy need
to be present unequivocally in the ﬁrst
step to enter the Turin criteria [2, 31,
39, 54]. Thus, CD31 staining or similar
vascularmarkers to substantiate angioin-
vasion are probably more helpful than
the aforementioned other antibodies.
About 40–70% of PDTC express
TP53—which does not always correlate
with the mutational TP53 gene sta-
tus—and an immunohistochemical loss
of the tumor suppressors p21 and p27
has also been observed [2, 31, 36].
Molecular alterations
BRAF mutations are seen in PDTC in
about 20% of cases and RAS mutations
in 20–40%. Both mutations can, how-
ever, also be found in PTC and FTC
([35]; . Fig. 3). The activation of MAPK
andPI3K–AKTsignalingpathways is im-
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Fig. 38 Stepwise de-diﬀerentiation of thyroid carcinomas derived from follicular epithelial cell
portant for thyroid cancer initiation and
progression. Consistent with this no-
tion, mutations in PIK3CA can be found
in a subset of FTC (10%) and in PDTC
cases (5–10%; [36]).
Mutations in the tumor suppressor
gene TP53 and EIF1AX are thought to
represent a late event in thyroid tumori-
genesis and can be detected in about 30%
and 11% of PDTC cases [29, 35]. These
mutations occur basically only in ad-
vanced thyroid carcinomas (PDTC and
ATC) and are almost never found inwell-
diﬀerentiated lesions like PTC or FTC
[11, 35]. The other mutation that is
a putative late event in thyroid cancer
progression is CTNNB1, which is never
found in well-diﬀerentiated cancers but
in PDTC in about 10–20% and in ATC in
up to 60% of cases. Mutations inMED12
and RBM10 are recently described mu-
tations in PDTC occurring in 12–15% of
cases and may represent novel markers
of aggressiveness [23].
Telomerase reverse transcriptase
(TERT) promoter mutations have been
reported in various thyroid malignancies
and are always associatedwith an adverse
outcome, probably due to an increased
telomerase activity [19, 32]. They occur
in two exclusive hotspots, C228T and
C250T, with a frequency of 33.8% and
15%, respectively, in PDTC, according
to a meta-analysis [32].
Rearrangements are found in 10–14%
ofPDTCs. These include rearrangements
of RET/PTC, BRAF, ALK, NTRK3, and
PAX8-PPRγ [57], which can be encoun-
tered in about 7% of cases according
to one study [7], while RET/PTC re-
arrangements also seem to be—if at
all—only evident in a small percentage
of cases [48]. These alterations are more
frequently found in well-diﬀerentiated
tumors—PAX8-PPRγ in FTC in about
12–30%andRET-PTC inPTC in10–20%
of cases [7, 36]. It is possible, but yet to
be proven, that these clones are less ag-
gressive and usually become outgrown
by more aggressive tumor parts with
other mutations and are therefore rarely
found in PDTC.
Owing to thevastoverlapofmutations
in the diﬀerent subtypes and the lack
of speciﬁc mutations, molecular testing
of PDTC as a diagnostic tool has not
found its way into clinical practice so
far. However, the deeper insight into
the molecular alterations and the new
tyrosine kinase inhibitors willmost likely
change this in the very near future to
ensure adequate patient treatment.
Comparative genomic hybridization
(CGH) shows large numbers of chro-
mosomal abnormalities in thyroid can-
cers. Gains of 5p15, 5q11–13, 19p, and
19q and loss of 8p suggest that these
tumors have a common signaling path-
way and origin, while gains of 1p34–36,
6p21, 9q34, 17q25, and 20q and losses
of 1p11-p31, 2q32–33, 4q11–13, 6q21,
and 13q21–31 most likely represent sec-
ondary events of progression as they are
only found in PDTC and ATC. Finally,
gains at 3p13–14 and 11q13 and loss of
5q11–31 are only found in ATC [56]. In
short, the number of gains and losses in
PDTC are in the range between well-dif-
ferentiated thyroid carcinomas andATC,
which have—unsurprisingly—the most
alterations [42, 56].
Epigenetic changes
MiRNA expression in poorly diﬀeren-
tiated carcinomas has been explored
and we know today that PDTCs have
a miRNA proﬁle that is not only dis-
tinctive from well-diﬀerentiated thyroid
carcinomas but that also separates PDTC
from oncocytic PDTC [16–18]. The con-
cept of tumor progression from PTC and
FTC to PDTC can also be observed on
the miRNA level where several miRNAs
known to be upregulated in thyroid
cancer like miR-221 and miR-222 are
increasingly deregulated in PDTC as
compared with PTC [18].
Long non-coding RNAs (lncRNAs)
are other non-protein coding transcripts
longer than 200 nucleotides that regu-
late proliferation and tumor recurrence.
Initial evidence shows that lncRNAsmay
be involved in thyroid tumor progression
and that they play a role in BRAF regu-
lation and in the MAPK pathway [46].
Prognosis
Poorly diﬀerentiated thyroid carcinomas
are aggressive lesions that require ap-
propriate diagnosis, treatment, and fol-
low-up. The relapse-free survival is less
than 12 months, the mean survival is
50–60 months, and 44% of patients die
of disease [2, 14]. Several factors have
been identiﬁed to aﬀect patient prog-
nosis. Among them are increased pa-
tient age of ≥45 years, large tumor size
of ≥5cm, macroscopically evident ex-
trathyroidal extension at surgery anddis-
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Table 1 Immunohistochemistry in diﬀerent thyroid carcinomas
Immunohistochemical staining MTC PTC FTC PDTC ATC
Calcitonin ++ – – – –
Chromogranin A ++ – – no data –
Synaptophysin ++ –/+ –/+ no data –
Thyroglobulin – +++ +++ –/+ –/+
Galectin-3 –/+ ++ –/+ –/+ –/+
HBME-1 –/+ ++ –/+ –/+ –/+
PanCK ++ ++ ++ + –/+
TTF1 ++ ++ ++ –/+ –
CK7 ++ ++ ++ –/+ –/+
CK19 –/+ ++ –/+ –/+ –
PAX8 – ++ –/+ –/+ –/+
MTCmedullary thyroid carcinoma, PTC papillary thyroid carcinoma, FTC follicular thyroid carcinoma,
PDTC poorly differentiated thyroid carcinoma, ATC anaplastic thyroid carcinoma
tant metastases at presentation [33], im-
munohistochemicalmarkers like insulin-
like growth factor mRNA-binding pro-
tein 3 (IMP3) and tumor necrosis factor
[2].
The mutational landscape of PDTC
continues to be deciphered and the
identiﬁed molecular markers of aggres-
siveness are TERT promoter, MED12,
RBM10, BRAF, HRAS, TP53, ATM, and
EIF1AX mutations [24, 32, 55]. Dereg-
ulation in the expression of miR-23b
and miR-150, both well-known tumor-
associated miRNAs, also seem to play
a role in PDTC and are suitable for
predicting patient outcome [18].
The oncocytic subtype may be associ-
ated with an evenworse clinical outcome
than conventional PDTC, possibly due
to a decreased radioiodine uptake that is
typical for oncocytic lesions in general
[15].
Treatment
There is no standardized treatment for
PDTC to date. However, it is accepted
that in general terms a more aggressive
approach is needed to treat these tumors
as compared with standard low-risk thy-
roid carcinomas [59]. If possible, a to-
tal thyroidectomy including lymph node
dissection shouldbeperformed. Accord-
ing to one study, total thyroidectomy and
removal of residual disease achieved a 5-
year regional control of 81% [22]. Ra-
dioiodine treatment is only successful in
a subset of patients owing to variable lev-
els of iodine uptake, although the exact
number of responders is unclear. Nev-
ertheless, given the high mortality rate
of the neoplasm and the potential ther-
apeutic beneﬁt, high-dose radioiodine
treatment is currently recommended for
all PDTC patients by a multidisciplinary
group of experts [45]. The same authors
recommend external beam radiation for
large tumors of >4cm with stage T3 and
T4 and for patients with regional lymph
node metastases [45]. However, little
has been published on PDTC and ex-
ternal beam radiation and recommen-
dations are solely based on extrapola-
tion from studies of well-diﬀerentiated
thyroid carcinomas (PTC/FTC) where
a treatment beneﬁt could be shown in
patients who are at high risk of local
recurrences [8]. Chemotherapy is cur-
rently not standard of care, althoughpos-
itive eﬀects have rarely been observed in
some patients [58]. By contrast, the role
of tyrosine kinase inhibitors is evolving
and they may be a new and promising
approach for treatingPDTC in the future.
In fact, after the results of the DECISION
and the SELECT trial were published,
sorafenib and lenvatinib were approved
by the U.S. Food and Drug Adminis-
tration (FDA) for patients with radioio-
dine-resistant progressive, recurrent, or
metastatic disease [10, 25, 47]. However,
we still do not know whether a speciﬁc
molecular signature predicts response to
a given tyrosine kinase inhibitor. It is
also unknown whether patients should
be treated in early or late stages, and the
actual beneﬁt in terms of patient survival
remains to be seen [52].
Summary
Poorly diﬀerentiated thyroid carcinomas
are aggressive lesions that severely impact
patients’ life and a correct diagnosis is
central for further patient management.
The Turin criteria, the diagnostic al-
gorithm facilitating a diagnosis of PDTC,
were established more than 10 years ago
and since then their utility has been
proven in multiple studies. The former
uncertainty among pathologists with
these lesions should be resolved and
PDTCs are now accepted as a separate
entity in the currentWHO classiﬁcation.
Some studies of epigenetic changes are
available and loss and gains of diﬀer-
ent chromosomes as well as miRNA
deregulation seem to be involved in
the development of PDTC. Despite
our growing knowledge on molecular
alterations in the thyroid, molecular
pathology has currently no central role
as a diagnostic tool of PDTC, mostly
owing to the concept of stepwise thyroid
cancer progression. Nevertheless, the
role of molecular pathology in conjunc-
tion with new tyrosine kinase inhibitors
will become increasingly important to
ensure adequate treatment in the era of
personalized medicine.
Practical conclusion
4 Poorly diﬀerentiated thyroid car-
cinomas are an underdiagnosed
entity.
4 An increasedmitotic index and tumor
necrosis in conjunction with a solid
trabecular or insular growth pattern
as described in the Turin proposal can
reliably diﬀerentiate between a well-
diﬀerentiated thyroid carcinoma
and a poorly diﬀerentiated thyroid
carcinoma.
4 A poorly diﬀerentiated area of only
10% within a thyroid carcinoma will
signiﬁcantly aﬀect patient prognosis.
4 Tyrosine kinase inhibitors oﬀer new
treatment options in these very
diﬃcult to treat tumors.
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4 Molecular mutational testing will
help in decision-making for targeted
therapies.
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